Rhabdomyolysis and Cardiomyopathy in a 20-Year-Old Patient with CPT II Deficiency. by Vavlukis, Marija & Kedev, Sasko
Case Report
Rhabdomyolysis and Cardiomyopathy in a 20-Year-Old Patient
with CPT II Deficiency
M. Vavlukis,1 A. Eftimov,2 P. Zafirovska,1 E. Caparovska,1 B. Pocesta,1
S. Kedev,1 and A. J. Dimovski2
1 University Clinic of Cardiology, Medical Faculty, Ss. Cyril and Methodius University, Mother Teresa 17, 1000 Skopje, Macedonia
2 Faculty of Pharmacy, Ss. Cyril and Methodius University, Mother Teresa 47, 1000 Skopje, Macedonia
Correspondence should be addressed to A. J. Dimovski; adimovski@ff.ukim.edu.mk
Received 30 September 2013; Accepted 6 November 2013; Published 20 January 2014
Academic Editors: D. J. Bunyan, P. D. Cotter, C. Julier, and B. Melegh
Copyright © 2014 M. Vavlukis et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Aim. To raise the awareness of adult-onset carnitite palmitoyltransferase II deficiency (CPT II) by describing clinical, biochemical,
and genetic features of the disease occurring in early adulthood. Method. Review of the case characteristics and literature review.
Results. We report on a 20-year-old man presenting with dyspnea, fatigue, fever, and myoglobinuria. This was the second episode
with such symptoms (the previous one being three years earlier). The symptoms occurred after intense physical work, followed by
a viral infection resulting in fever treated with NSAIDs. Massive rhabdomyolysis was diagnosed, resulting in acute renal failure
necessitating plasmapheresis and hemodialysis, acute hepatic lesion, and respiratory insufficiency. Additionally, our patient had
cardiomyopathy with volume overload. After a detailed workup, CPT II deficiency was suspected. We did a sequencing analysis for
exons 1, 3, and 4 of the CPT II gene and found that the patient was homozygote for Ser 113 Leumutation in exon 3 of the CPT II gene.
The patient recovery was complete except for the cardiomiopathy with mildly impaired systolic function. Conclusion. Whenever
a patient suffers recurrent episodes of myalgia, followed by myoglobinuria due to rhabdomyolysis, we should always consider the
possibility of this rare condition. The definitive diagnose of this condition is achieved by genetic testing.
1. Introduction
Carnitine palmitoyltransferase (CPT) deficiencies are genetic
disorders of mitochondrial fatty acid oxidation. Long-chain
fatty acids are required for fueling the skeletal muscles
and are only able to cross mitochondrial membrane after
esterification with carnitine in a reaction with the enzyme
CPT I. Inside themitochondria, the fatty acid is reactivated to
acyl-CoA from acylcarnitine and CoA with the help of CPT
II in order to enter the 𝛽-oxidation cycle [1–3].
The CPT II deficiency presents in three different forms:
lethal neonatal form; severe infantile hepatocardiomuscular
form, and adult-myopathic form [1–8].
The adult-myopathic form is the most prevalent type of
the disease with about 300 cases reported. The first descrip-
tion was made in 1973 by the brothers Di Mauro. The first
symptomsmost often occur between 6 and 20 years of age but
the age of onset may be over 50 years and as early as 8 months
of life [9, 10]. The symptomatology usually consists of recur-
rent attacks of rhabdomyolysis presenting asmyalgias,muscle
stiffness andweakness, andmyoglobinuria. In rare situations,
rhabdomyolysis may result in life-threatening complications
such as acute renal failure and respiratory insufficiency
secondary to respiratory muscles involvement [11, 12].
We are describing such a clinical case.
2. Case Presentation
We report a case of a 20-year-old man transferred to our
clinic under suspicion of myocarditis. He presented with dys-
pnea, fatigue, myalgia, fever, and myoglobinuria. The patient
reported those three days before becoming symptomatic, he
was subjected to a more intense physical work (unloading a
truck). The next day he felt like coming down with a cold,
he felt weak and had muscle pains. Later that day, he was
admitted to the ER with fever (40∘C) where he received
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Figure 1: Strain analysis of the left ventricle.
a parenteral therapy with NSAIDs. After the parenteral ther-
apy, he complained ofworsening of the symptomswith strong
myalgia, dyspnea, fatigue, sweating, and myoglobinuria.
Influenza B was identified, and increased markers of
inflammation-fibrinogen, CRP, leukocytosis, plasma levels of
CPK up to 114000 IU, CK-MB 5400 IU, and myoglobin up
to 33000 IU were detected, resulting in acute renal failure
(necessitating plasmapheresis and hemodialysis treatments),
respiratory insufficiency (necessitating a noninvasive ventila-
tion support), and a mild to moderate hepatic lesion.
During the whole period, the blood glucose levels were
in the range of 3, 4-5, 4mmol/L (lower normal limit), and no
significant hypoglycemia was registered.
Muscle biopsy identified exacerbated chronic vasculitis
with atrophy of certain muscle cells. The immunologic
markers and hemoculture were negative. The pneumoslide
was only positive to IgM for Influenza B.
The echocardiographic examination revealed enlarged
left ventricle (LVEDd 65; LVEDs 48) with EF of 47% by
the Simpson method. Strain analysis using speckle tracking
identified GLPS average of −13.8% (Figure 1).
After one-month hospitalization period, the patient was
stabilized and discharged from the hospital. During the nine-
month follow-up period he was stable, completely recovered,
and asymptomatic, except for a mildly impaired left ventric-
ular systolic function.
His prior history revealed that the patient used to feel
cramps and pain in the legs after prolonged walking in the
childhood. He experienced a similar episode three years
earlier after prolonged exercise (body building for several
hours), exposure to a cold temperature, and infection (febrile
illness), when he was hospitalized in another institution with
severe signs of rhabdomyolysis (creatinine phosphokinase up
to 42000 IU) and hepatic lesion (AST, ALT up to ×10 over
the upper limit) and was diagnosed with cardiomyopathy
with increased LV dimensions LVEDd > 60mm, EF 45%.
There were no signs of renal impairment at that time. He was
stabilized and discharged from hospital. During attack-free
periods, the patient was asymptomatic.
The patient had a deceased father from heart failure of
unknown origin and a sister that died at the age of 18 months
in unclear circumstances after “being sick all the time” when
she received an injection for fever.
During hospitalization, the diagnosis of CPT II deficiency
was suspected and the patient was referred for genetic
analyses. Sequencing analysis of exons 1, 3, and 4 of theCPT II
gene revealed that the patient was homozygote for Ser 113 Leu
mutation (Figure 2). Diagnosis of adult myopathic form of
carnitine palmitoyltransferase II deficiency was made based
on the genetic findings and signs and symptoms as well as the
age of onset.
3. DNA Sequencing
DNA was extracted from a peripheral blood sample using
QiAmp DNA Blood Mini Kit (Qiagen). Exons 1, 3, and 4 of
the CPT II gene were amplified by PCR using the following
oligonucleotide primer pairs: CPT2 Ex 1 F: 5󸀠-ACTCCA-
GAACTCCCCACTTG-3󸀠/CPT2 Ex 1 R: 5󸀠- CGGGTTCAC-
TAGAGGAGTCA-3󸀠 (299 bp PCR fragment); CPT2 Ex 3
F: 5󸀠-CCTCGCCATGAACCTAAAAA-3󸀠/CPT2 Ex 3 R: 5󸀠-
TTCATTATGGAGGGCTCTGG-3󸀠 (231 bp PCR fragment);
CPT2 Ex 4 F: 5󸀠-CCCATTAAGGACCTTGTCCA-3󸀠, CPT2
Ex 4 R: 5󸀠-GCCTCAGAGCACCTCTTTGT-3󸀠 (564 bp PCR
fragment). Direct sequencing was performed at 3500 Series
AB Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA).
4. Discussion
Carnitine palmitoyltransferase (CPT) CPT I deficiency is a
very rare condition and is recognized in three different forms,
of which the last two have not been identified in humans yet
(might be incompatible with life): liver type CPT I deficiency;
muscle-type and brain-type CPT I deficiency [1–3].
The CPT II deficiency presents in three different forms:
(i) lethal neonatal form,
(ii) severe infantile hepatocardiomuscular form, and
(iii) adult-myopathic form [1–6].
The lethal neonatal form is characterized by episodes of
liver failure, hypoketotic hypoglycemia, cardiomyopathy, car-
diac arrhythmias, seizures and coma after fasting or infection,
and facial and structural abnormalities [4]. This presentation
is fatal; the CPT II activity is barely detectable in any of the
tissues, leading to death in the neonatal period [2, 7].
Case Reports in Genetics 3
A AT TT T T G G G G
1652 1666 1600 1624 1700 17921736 1750 1764 17701722
140 141 142 143 144 145 146 147 148138 139
(a)
A AT TT T H G G G G
1652 1666 1600 1624 1700 17921736 1750 1764 17701722
141 142 143 144 145 146 147 148 149139 140
(b)
A AT TT T CC G G G G
1652 1666 1600 1654 1700 1792 1750 1764 17751722
139 140 141 142 143 144 145 146 147137 138
(c)
Figure 2: Sequencing analysis demonstrating the detection of TCG > TTG or S113L mutation in exon 3 of the CPT II gene (a: patient; b:
mother of the patient; c: normal control).
The severe infantile hepatocardiomuscular form is char-
acterized by liver failure, cardiomyopathy, seizures, hypoke-
totic hypoglycemia, peripheral myopathy, and attacks of
abdominal pain. The onset is more often before one-year
of age and usually ends with a sudden death secondary to
paroxysmal heart beat disorders [2, 4, 8].
The adult-myopathic form is the most prevalent type of
the disease with about 300 cases reported.Themajority of the
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patients are males (∼80%) and it is inherited in an autosomal
recessive manner. The first description was made in 1973 by
the brothers Di Mauro. The first symptoms most often occur
between 6 and 20 years of age but the age of onset may
be over 50 years and as early as 8 months of life [9, 10].
The symptomatology usually consists of recurrent attacks of
rhabdomyolysis presenting as myalgias, muscle stiffness and
weakness, and myoglobinuria. The frequency of the symp-
toms is highly variable and they resolve within hours to days
with clinically symptom-free periods between attacks. The
rhabdomyolysis may occasionally be complicated by three
kinds of life-threatening events, that is, acute renal failure
due to myoglobinuria, respiratory insufficiency secondary
to respiratory muscles involvement, and paroxysmal heart
arrhythmias [11, 12]. The symptoms are usually provoked
by prolonged exercise, fasting, high fat intake, exposure to
cold, infections accompanied by fever, and general anesthesia
and drugs such as ibuprofen, diazepam, and valproic acid.
In general, the patients have normal life expectancy with
complications such as acute kidney failure in massive rhab-
domyolysis, usually sparing other organs. In our patient we
observed cardiac complications.
Our patient presented with all the typical signs and
symptoms, including a respiratory failure combined with
heart failure, probably worsened by volume overload during
the uric period of the disease.The findings of the echocardio-
graphy examinations done three years earlier and at present
time identify dilated cardiomyopathy with a reduced ejection
fraction. The strain analysis using speckle tracking showed
average GLPS decrease of 13.8%. These findings could be
prescribed to the nature of the disease and consequence of
lipid storage in the myocardium even though unspecific for
this form of disease. Could myocardial biopsy help us with
our hypothesis? Comparisons with the results obtained three
years ago showed a relatively stable course of heart failure
(no significant progression of the left ventricle dimension or
reduction of the ejection fraction).
Diagnosing CPT II deficiency can be done by acylcarni-
tine analysis using tandemmass spectrometry (peak at C16 is
indicative of the condition).Measurement of theCPT II activ-
ity can be performed aswell asmany laboratory findings, such
as low carnitine levels, increased serum creatinine kinase,
and transaminase, which can be associated with the disease.
For a definitive diagnosis, sequencing of the CPT II gene for
a mutation analysis is recommended. The CPT II gene has
been assigned to chromosome 1p32. It contains five exons and
more than 25 mutations have been described [3]. The S113L
is the most common mutation in the myopathic form. There
is evidence that the S113L mutation leads to a thermolabile
CPT II protein whose activity is reduced when the body
temperature is high, as with exercise, fever, or heat stress [13].
Definitive diagnosis in our patient was established with
the CPT II gene sequencing formutation analysis, and the Ser
113 Leu mutation in exon 3 of the CPT II gene was identified
(Figure 2). Genetic analyses were performed on the patient’s
family (mother and two siblings). We found that his mother,
brother, and sister are carriers for the mutation, but none
of them described any myalgia or symptoms suggestive of
rhabdomyolysis.
The treatment of this condition consists of hygiene-
dietary changes that would prevent attacks and symptomatic
treatment ofmyoglobinuria and possible renal complications.
Patients are advised to reduce the intake of long-chain dietary
fat and increase the consumption of meals rich in carbo-
hydrates. They should have more frequent meals and avoid
fasting. Other things that should be avoided include pro-
longed exercise as well as some drugs (ibuprofen, diazepam,
valproic acid, and general anesthesia). During intercurrent
infections infusion of glucose can be administered. Oral
carnitine supplementation can be considered as an adequate
therapy. The medium-chain fatty acid triheptanoin may be
effective in the adult-onset CPT II deficiency.
At present, nine months after this episode, our patient
is clinically stable and no episodes of rhabdomyolysis have
been registered. He is on heart failure treatment medications,
and he is following the advice given to him concerning his
life style modification. He does not work as a lorry driver
anymore.
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